Longer telomere length associated with increased lung cancer risk

A large-scale genetic study of the links between telomere length and risk for five common cancers finds that long telomeres are associated with an increased risk of lung adenocarcinoma. No significant associations between telomere length and other cancer types or subtypes were observed. The findings were published in Human Molecular Genetics (2015; doi:10.1093/hmg/ddv252).

The study, led by scientists from the University of Chicago in Illinois, uses a novel method to measure genetic predisposition for telomere length, rather than physiological measures which are confounded by factors such as age and lifestyle.

"Our work provides compelling evidence of a relationship between long telomeres and increased risk for lung adenocarcinoma," said study leader Brandon Pierce, PhD, assistant professor of public health sciences at the University of Chicago. "The prevailing hypothesis has been that short telomeres are bad for health, but it appears that this does not necessarily translate to some types of cancer."

Telomeres are protective caps of DNA that prevent damage to the ends of chromosomes. A portion of the telomere DNA is lost during cell division. This leads to telomere shortening over time, which has been thought of as a time-delay fuse that can trigger cell death or genomic instability. Shortened telomeres have been implicated in aging and cardiovascular diseases, but their relationship with cancer risk is thus far unclear. Because telomeres can vary greatly due to factors such as age, lifestyle, and cancer progression, efforts to study the direct associations between cancer risk and telomere length have been difficult.

To address this issue, Pierce and his colleagues used Mendelian randomization, a method which calculates telomere length based on genetic factors. They created a score based on a combination of genetic variants identified by prior genome-wide association studies as being associated with telomere length. Since genetics remain unchanged even as telomeres physically shorten, this measurement allowed for unbiased comparisons to cancer risk.

Using genome data from more than 50,000 cancer cases and 60,000 controls through the GAME-ON (Genetic Associations and Mechanisms in Oncology) network, the team compared telomere lengths with the risk of developing breast, lung, colorectal, ovarian, and prostate cancers, including subtypes.

They found that longer telomeres were significantly associated with increased risk for lung cancer, specifically lung adenocarcinoma, which more than doubled in risk for every 1,000 base pair increase in telomere length. Surprisingly, the researchers found no associations between shortened telomeres and cancer risk. Aside from lung cancer, only prostate cancer risk showed a modest positive association with long telomeres.

"Mendelian randomization is an important tool that allows us to examine telomere length without the problematic biases that come with physically measuring it," said study author Chenan Zhang, graduate student in public health sciences at the University of Chicago. "The positive association between telomere length and lung adenocarcinoma should be further investigated with the long term goal of improving prediction and prevention of this common cancer subtype."

The team suggests a potential explanation for this observation is that long telomeres enable more rounds of cell division than short telomeres, which could allow cells to live longer and have more opportunities to accumulate carcinogenic mutations.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs